Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold

 
• By Alaric DeArment
  
Foghorn announced a partial clinical hold on its Phase I AML/MDS study following a patient death • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D